2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)

Axsome Therapeutics is expected to expand its approved product lineup and, according to the article, face no generic competition through 2036. Eli Lilly is described as a leader in its core market, with potential to diversify its lineup over the long run.